Regulation of G Protein-linked Guanine Nucleotide Exchange Factors for Rho, PDZ-RhoGEF, and LARG by Tyrosine Phosphorylation: Evidence of a Role for Focal Adhesion Kinase
Overview
Affiliations
A recently identified family of guanine nucleotide exchange factors for Rho that includes PDZ-RhoGEF, LARG, and p115RhoGEF exhibits a unique structural feature consisting in the presence of area of similarity to regulators of G protein signaling (RGS). This RGS-like (RGL) domain provides a structural motif by which heterotrimeric G protein alpha subunits of the Galpha(12) family can bind and regulate the activity of RhoGEFs. Hence, these newly discovered RGL domain-containing RhoGEFs provide a direct link from Galpha(12) and Galpha(13) to Rho. Recently available data suggest, however, that tyrosine kinases can regulate the ability of G protein-coupled receptors (GPCRs) to stimulate Rho, although the underlying molecular mechanisms are still unknown. Here, we found that the activation of thrombin receptors endogenously expressed in HEK-293T cells leads to a remarkable increase in the levels of GTP-bound Rho within 1 min (11-fold) and a more limited but sustained activation (4-fold) thereafter, which lasts even for several hours. Interestingly, tyrosine kinase inhibitors did not affect the early phase of Rho activation, immediately after thrombin addition, but diminished the levels of GTP-bound Rho during the delayed phase. As thrombin receptors stimulate focal adhesion kinase (FAK) potently, we explored whether this non-receptor tyrosine kinase participates in the activation of Rho by GPCRs. We obtained evidence that FAK can be activated by thrombin, Galpha(12), Galpha(13), and Galpha(q) through both Rho-dependent and Rho-independent mechanisms and that PDZ-RhoGEF and LARG can in turn be tyrosine-phosphorylated through FAK in response to thrombin, thereby enhancing the activation of Rho in vivo. These data indicate that FAK may act as a component of a positive feedback loop that results in the sustained activation of Rho by GPCRs, thus providing evidence of the existence of a novel biochemical route by which tyrosine kinases may regulate the activity of Rho through the tyrosine phosphorylation of RGL-containing RhoGEFs.
McDuffie E, Panettieri Jr R, Scott C Respir Res. 2024; 25(1):295.
PMID: 39095798 PMC: 11297630. DOI: 10.1186/s12931-024-02920-0.
Zhang J, Wei K, Qu W, Wang M, Zhu Q, Dong X J Neurosci. 2023; 43(25):4559-4579.
PMID: 37225434 PMC: 10286951. DOI: 10.1523/JNEUROSCI.1962-22.2023.
Regulation of Leukaemia Associated Rho GEF (LARG/ARHGEF12).
Ghanem N, Matter M, Ramos J Small GTPases. 2021; 13(1):196-204.
PMID: 34304710 PMC: 9707526. DOI: 10.1080/21541248.2021.1951590.
Panagopoulos I, Andersen K, Eilert-Olsen M, Zeller B, Munthe-Kaas M, Buechner J Cancer Genomics Proteomics. 2021; 18(1):67-81.
PMID: 33419897 PMC: 7796818. DOI: 10.21873/cgp.20242.
The PAR2 inhibitor I-287 selectively targets Gα and Gα signaling and has anti-inflammatory effects.
Avet C, Sturino C, Grastilleur S, Le Gouill C, Semache M, Gross F Commun Biol. 2020; 3(1):719.
PMID: 33247181 PMC: 7695697. DOI: 10.1038/s42003-020-01453-8.